Two GPU Stocks, One Week, Opposite Signals

China's home-grown AI chip sector delivered a split screen in early September. On September 2, Tencent-backed Enflame Technology priced a roughly 6.1 billion yuan ($908 million) Shanghai STAR Market IPO at 142.18 yuan a share, valuing the loss-making chipmaker at about 61 billion yuan ($9.1 billion) — nearly 62 times 2025 sales — after retail investors oversubscribed the offering 6,109 times 1 2 3. Five days later, Moore Threads, the cohort's pioneer and the first of the so-called four little GPU dragons to list, fell by its 20% daily limit as a nine-month IPO lockup expired, dragging the stock from a 52-week high near 941 yuan to roughly 387 yuan by September 9 5 6. For investors, the juxtaposition is the story: the market's appetite for unprofitable Chinese AI silicon is still voracious at the point of entry, and still untested at the point of exit.

The Fourth Dragon Prices at a Premium

Enflame completes the public listing of China's four leading GPU-design startups — Moore Threads, Biren Technology, MetaX Integrated Circuits and now Enflame — all born from the same structural bet: that US export controls on Nvidia's most advanced accelerators would force a captive domestic market into their arms. Enflame's own numbers show why investors are willing to pay nearly 62 times revenue for a company that has never turned a profit. Revenue grew from 301 million yuan in 2023 to 990 million yuan in 2025, an 81% three-year compound annual growth rate, while net losses narrowed from 1.665 billion yuan to 1.164 billion yuan over the same stretch 4. Management is guiding to full profitability in 2026 or 2027, and expects first-half 2026 revenue to more than triple year-on-year to between 10.6 billion and 11.5 billion yuan, even as it still forecasts a roughly 600 million yuan loss for that same half 4.

One Customer, Nearly All the Revenue

The prospectus also flags the risk sitting underneath the growth curve: Tencent accounted for 71.84% of Enflame's 2025 revenue, and Enflame holds an estimated 1.4% share of China's domestic AI-chip market 4. That concentration is not unique to Enflame — it is close to the template for the whole cohort, whose STAR Market and Hong Kong listings were effectively engineered to convert a handful of hyperscaler procurement contracts into public-market valuations years before the underlying chip businesses were commercially proven at scale. Investors buying into the IPO are, in practice, buying a leveraged bet on one or two customers renewing large orders in an environment where Beijing is actively steering state-linked cloud spending toward domestic silicon.

The Cohort's First Reality Check

Moore Threads is the read-through for what happens once that bet has to clear a public float. Its December 5, 2025 debut on the STAR Market was euphoric — shares surged more than 400% from a 114.28 yuan offer price to close at 600.5 yuan 5. Fundamentals then caught up more slowly than the share price: first-half 2026 revenue rose 147% year-on-year to 1.736 billion yuan, but the company still posted a net loss attributable to shareholders of about 11.56 million yuan 6. The September 7 lockup expiry, which freed pre-IPO shareholders to sell for the first time, triggered the limit-down move and erased a large share of the post-listing premium in a single session 5 6. It is a preview of the mechanical pressure Enflame, Biren and MetaX will each face on their own lockup dates.

A Diverging Field

Not all four dragons are moving in the same direction. Biren, which jumped almost 76% on its January 2 Hong Kong debut from an HK$19.60 offer price to HK$34.46 7, is still unprofitable but narrowing losses quickly — its first-half 2026 loss is projected at 320 million to 400 million yuan, down 75-80% from a year earlier. MetaX, by contrast, has already crossed into the black: it swung to a 612 million yuan net profit in the first half of 2026, reversing a 186 million yuan loss a year prior, even as Biren and Enflame remain deep in the red 8. That divergence matters for anyone treating the group as a single trade — the market has so far priced all four at growth-stock multiples regardless of which ones are actually approaching sustainable earnings.

What It Means for Investors

The near-term signal to watch is not the next IPO but the next lockup. Biren's and MetaX's own restricted-share unlocks, and Enflame's first anniversary on the STAR Market, will each test whether retail demand of the kind that produced a 6,109-times subscription can hold once early backers are free to sell. The deeper signal is customer concentration: with 70%-plus of revenue tied to one hyperscaler in Enflame's case, and similar patterns across the cohort, these are not yet diversified chip franchises so much as proxies for a small number of state-linked procurement decisions. For investors positioned in China's AI-hardware self-sufficiency trade, the more useful comparison than any single valuation multiple is Moore Threads' chart: a 400% debut pop is not evidence of a durable business, and the first real test of these listings arrives roughly nine months after the ribbon-cutting, not on the first day of trading.